13 news items
Bio-Path Holdings Reports First Quarter 2024 Financial Results
BPTH
15 May 24
® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
BPTH
8 May 24
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAOI
AGBA
AGRI
22 Apr 24
and raised its price target from $62 to $70.
Ingevity Corporation
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BPTH
19 Apr 24
of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq
Bio-Path Holdings Announces $1.2M Registered Direct Offering With Some Institutional Investors For Sale Of 375,000 Shares Of Its Common Stock At Price Of $3.225/Share
BPTH
18 Apr 24
"), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid
956ucs613ztui5gqyg9a2l3mbnvi5qgry6aj2qtfzwrei8tbu8omkqei
BPTH
18 Apr 24
of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance
2vupb3lifzl2su0bsjtyf24csndwxkdjjy8a80lkg0l cxllmjpgqpfdsxz
BPTH
18 Apr 24
Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $40 price target.
ab581a2fdtbn3sdjf110puux
BPTH
18 Apr 24
:
BP1002 targets the protein
3q2wakn5dkzp3bbogrzke4qrpkh8 3rhn2g0z23mh17ljp3pl
AGBA
ALRN
APOG
18 Apr 24
Thalmann analyst Aydin Huseynov maintained Aileron Therapeutics with a Buy and raised the price target from $9 to $19.
MicroCloud
t2r47ju9q fo0huef9ivi7eka0pq5x9ei6jxhnxg
BPTH
18 Apr 24
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer
khsz93uplqtgb63sy0ci1onfguvrvnf5hy6wi h6qy2nvz4o82
BPTH
2 Apr 24
company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid
bqfvuyrf1utokhbhx9pcaawo2 psgzlhqgk6xigzgy3vtny3om6a
BPTH
8 Mar 24
company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid
up67 pjgz9uxmzrpyfueno7dzy2yl
BPTH
1 Mar 24
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer
- Prev
- 1
- Next